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A Causative Relationship between Mutant IFNgR1
Alleles and Impaired Cellular Response to IFNg in a
Compound Heterozygous Child
To the Editor:
Mutations in the IFNgR1 gene have recently been iden-
tified in two consanguinous kindreds from Malta and
Tunisia (Jouanguy et al. 1996; Newport et al. 1996).
Affected children were found to be homozygous for two
different alleles. No IFNgR1 protein molecules could be
detected at the surface of peripheral blood cells, ac-
counting for impaired IFNg-mediated immunity. Pa-
tients had disseminated infections due toMycobacterium
bovis, bacille Calmette Gue´rin (BCG) vaccinal strain, or
environmental nontuberculous mycobacteria (NTM),
such as M. avium, M. fortuitum, and M. chelonei (MIM
209950). No other opportunistic infections were doc-
umented, with the possible exception of salmonellosis in
one child, and four of five affected children died of my-
cobacterial infection. Thus, complete IFNgR1 deficiency
appears to be an autosomal recessive immune disorder
associated with severe and selective susceptibility to
poorly pathogenic mycobacteria.
To better characterize this condition, it is important
to demonstrate that there is a genuine causal relationship
between mutant IFNgR1 alleles and impaired cellular
responses to IFNg. It is also important to determine
whether compound heterozygous mutations of the
IFNgR1 gene may be responsible for BCG or NTM in-
fections in other kindreds (Casanova et al. 1995, 1996;
Levin et al. 1995; Emile et al. 1997). We have therefore
investigated an Italian child, born to nonconsanguinous
parents, who presented at 3 years of age with dissemi-
nated infection due to M. smegmatis (Pierre-Audigier et
al. 1997). The child was not vaccinated with BCG and
died at 8 years of age of a progressive mycobacterial
disease, despite intensive antimycobacterial therapy.
Four older siblings had received the BCG vaccine in in-
fancy with no adverse effect and were healthy.
To facilitate the genetic analysis of IFNgR1 deficiency,
we first identified an intragenic polymorphic CA-repeat,
designated “FA1” (fig. 1). The IFNgR1 gene has been
previously mapped to the broad chromosome region
6q16–6q22, by use of somatic cell hybrids (Pfizenmaier
et al. 1988), and to 6q24.1–6q24.2, by in situ hybrid-
ization (Le Coniat et al. 1989; Pappanicolaou et al.
1997). The segregation of FA1 alleles within CEPH ref-
erence families provided a genetic mapping of FA1 be-
tween D6S292 (centromeric) and D6S1699 (telomeric)
(4 cM). Physical mapping of the gene and surrounding
markers on a YAC contig was then achieved. Intrafam-
ilial genotyping showed that the affected child had a
unique pattern for FA1 and the associated D6S1009,
D6S310, and D6S1587 microsatellites, when compared
with her four healthy siblings (not shown). This segre-
gation was compatible with the diagnosis of autosomal
recessive IFNgR1 deficiency.
Amplification of the seven IFNgR1 exons and asso-
ciated intronic consensus splice sites was performed for
each member of the family. Sequencing revealed a 4-bp
insertion, designated “107ins4,” within IFNgR1 exon 2
at one locus in the child and in the father (not shown).
The four inserted nucleotides (TTAC) were found to du-
plicate flanking nucleotides 104–107, as has occasion-
ally been observed with insertions causing other genetic
diseases (Cooper and Krawczak 1991). The frameshift
is expected to cause premature termination of translation
before the transmembrane segment, because of a stop
codon at nucleotides 115–117. A substitution of the first
base of the consensus splice-donor site of IFNgR1 intron
3 was found at the other locus in the child and in the
mother, designated “2001GrA” (not shown). This
type of 5′ splice-site mutation is frequent in other genetic
diseases and is expected to cause exon 2 skipping and/
or cryptic splice-site usage (Krawczak et al. 1992). The
affected child was the only member of the family car-
rying the two mutant alleles, further suggesting that he
had IFNgR1 deficiency.
Analysis of IFNgR1 mRNA in the patient’s fibro-
blasts, by northern blot and amplification of the full-
length IFNgR1 cDNA coding region, failed to detect any
alternative splicing product, when compared with
healthy individuals (not shown). Likewise, amplification
of the patient’s cDNA, with primers specific for exon 1
(sense) and exon 3 (antisense), failed to detect exon 2
skipping and cryptic site usage. Even though the patient’s
IFNgR1 mRNA appeared to be of normal molecular
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Figure 1 Genetic and physical map of the IFNgR1 gene. Restriction digests of cosmids COSTCFP-2.8 and COSTCFP-7.13, carrying the
IFNgR1 gene (Merlin et al. 1997), were hybridized with a peroxydase-labeled (CA)30 probe. A specific fragment was found to contain a repeat
consisting of 22 CAs located in the sixth intron (FA1; Genbank accession number U84721). When tested on 80 unrelated individuals, this
marker was found to be highly informative, with 12 alleles and 190% heterozygosity. Linkage analyses were performed on three-generation
CEPH families genotyped with polymorphic markers (Dausset et al. 1990). The FA1 marker was positioned on a framework consisting of the
map of 5,264 markers (Dib et al. 1996), by use of the GMS algorithm (Lathrop and Lalouel 1988). On the basis of the best-supported order
for the framework map, recombination fractions between adjacent markers were estimated using the LINKAGE program (Lathrop et al. 1984).
The map was reevaluated until no further double recombination event could be eliminated. The FA1 microsatellite was thus genetically mapped
between microsatellites D6S292 and D6S1699 (!4 cM). The CEPH YAC WC6.15 contig was previously reported with a series of polymorphic
and nonpolymorphic markers (Dausset et al. 1992). Selected YACs of this contig were confirmed by PCR, to define a smaller contig encompassing
the microsatellite FA1 and its flanking markers defined by the genetic mapping. The physical map of the region was then enriched by testing
an additional panel of dinucleotide (Dib et al. 1996) and tetranucleotide (Sheffield et al. 1995) repeats on the same subset of YACs. The YAC
contig consisting of 905B7, 969D9, 846C12, and 778B11 spans !4 Mb. All markers positioned on this contig are polymorphic CA repeats,
except D6S1009 and D6S1003 (polymorphic tetranucleotide repeats) and D6S1319 (nonpolymorphic marker). The relative positions of D6S310
and D6S1587 and of D6S1569 and D6S1699 are not known.
weight and to be expressed at a normal level by northern
blot, the patient’s IFNgR1 cDNA-PCR, however, was
found to be 4 bp longer than the wild type. Moreover,
direct sequencing of the amplicon confirmed that the
only detectable IFNgR1 mRNA species in this patient
was encoded by the 107ins4 mutant allele. Together,
these results suggest that the 107ins4 allele transcript is
expressed at a normal level and that none of the
2001GrA allele potential transcripts, including full-
length, exon 2 skipping, and cryptic splice-site tran-
scripts, is detectable.
We then analyzed cell surface expression of the re-
ceptor by flow cytometry with two IFNgR1-specific an-
tibodies as reported elsewhere (Jouanguy et al. 1996).
Whereas IFNgR1 molecules were present on the surface
of peripheral blood mononuclear cells from healthy in-
dividuals, there were no detectable IFNgR1 molecules
on the patient’s cells (not shown). These data are con-
sistent with the analysis of IFNgR1 mRNA expression
and strongly suggest that both the 107ins4 and
2001GrA mutations preclude transcription of full-
length wild-type mRNA and expression of detectable
IFNgR1 molecules at the cell surface.
To document a functional defect in this patient, we
took advantage of a previously reported method for the
investigation of human leukocyte antigen (HLA)–class
II deficiency (Lisowska-Grospierre et al. 1994) and an-
alyzed the IFNg-mediated induction of HLA-DR in fi-
broblasts. Concentrations of IFNg, witin the range of
10–100,000 UI/ml, were tested for the induction of
HLA-DR after 48 h and 72 h of incubation. In all con-
ditions, there was no induction of HLA-DR on the pa-
tient’s cells, as detected by flow cytometry, in contrast
to the dramatic induction obtained with control cells
after only 48 h in response to x10 UI of IFNg/ml (fig.
2A). Intracellular HLA-DR could also be detected by
microscopic immunofluorescence in control cells but not
in the patient’s cells (not shown). These results suggested
that the patient’s fibroblasts were not responsive to IFNg
because of a lack of functional surface IFNgR1
molecules.
Finally, we attempted to demonstrate a causal rela-
tionship between the two mutant IFNgR1 alleles iden-
tified and impaired cellular response to IFNg. We thus
transiently transfected the patient’s fibroblasts with
wild-type IFNgR1 allele and assessed the induction of
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Figure 2 Impaired IFNg-mediated induction of HLA-DR on the
patient’s fibroblasts and complementation with wild-type IFNgR1
gene. A, Flow cytometry analysis of HLA-II on fibroblasts before
(dashed lines) and after (solid lines) addition of IFNg in a control (left)
and the patient (right). An adherent fibroblastic cell line was estab-
lished from a skin biopsy of the patient, grown in RPMI 1640 (Gibco
BRL) supplemented with 10% FCS (Gibco BRL) (complete medium)
and transformed with SV40T as described elsewhere (Lisowska-Gros-
pierre et al. 1994). One million fibroblastic cells were treated with 200
IU recombinant human IFNg/ml (Genex, Biogenex Laboratories) for
48 h, and the induction of HLA-DR was documented following tryp-
sinization by flow cytometry with a fluorescein isothiocyan-
ate–conjugated monoclonal antibody anti–HLA-DR (Becton Dickin-
son). B, Microscopic fluorescence analysis of IFNg-induced HLA-II
expression in the patient’s fibroblasts transiently transfected with con-
trol plasmid (left) and with IFNgR1 expression vector (right). The
fibroblasts were transferred to sterile microscopic slides for54# 10
in situ electrophoration in 100 ml of 10 mM sodium phosphate, pH
7.2, 1 mM MgCl2, and 250 mM sucrose with 4 mg plasmid DNA
(either an IFNgR1 expression vector referred to as “pSFFVhgR” or
the vector with no insert, referred to as “pSFFVneo”) (Farrar et al.
1991). Six pulses were delivered (5 ms, 320 V, 1 Hz, E 
) with a JOUAN GHT 128/A electropulser, and 5 min later0.8 kV/cm
the slides were placed in complete medium. After 3 h of culture, re-
combinant IFNg was added at 10 IU/ml, and after 24 h the medium
with IFNg at the same concentration was replaced. Antibody binding
(Bu27) on ethanol-fixed fibroblasts at 48 h following transfection was
revealed ,as described elsewhere (Lisowska-Grospierre et al. 1994).
Immunofluorescence analysis was carried out with a Leitz Orthoplan
optical microscope.
intracellular HLA-DR in response to IFNg, by micro-
scopic immunofluorescence. In response to even low
IFNg concentrations (10 UI/ml) and after only a brief
incubation (48 h), a number of cells intensely fluoresced,
attesting that transfection of the IFNgR1 gene conferred
normal IFNg-dependent induction of HLA-DR in the
cytoplasm (fig. 2B). By contrast, transfection of the con-
trol vector was ineffective in inducing intracellularHLA-
DR. Similar results were obtained with high concentra-
tions of IFNg (100,000 UI/ml) and 72-h incubation (not
shown). Analysis of HLA-DR surface expression by flow
cytometry was also consistent with these results (not
shown).
We have thus demonstrated a cause-and-effect rela-
tionship between mutant IFNgR1 alleles and impaired
cellular response to IFNg in this kindred. These data
corroborate the results previously obtained for two kin-
dreds and strengthen the association between inherited
IFNgR1 deficiency and susceptibility to mycobacteria in
affected children. This kindred provides further impor-
tant information concerning IFNgR1 deficiency. The af-
fected child was found to be the first compound heter-
ozygous patient. Worthy of note, the two mutations
found in this child were different mutations from the
two identified in previous kindreds. The four mutations
identified, to date, include a nonsense mutation, a de-
letion, an insertion, and a splice mutation. Thus, these
data not only show that the disease is not limited to
consanguinous families but also suggest that there is
probably a relatively high allelic heterogeneity under-
lying inherited IFNgR1 deficiency.
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